

# Sheila F O'brien

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4948623/publications.pdf>

Version: 2024-02-01

73  
papers

1,199  
citations

361413

20  
h-index

454955

30  
g-index

78  
all docs

78  
docs citations

78  
times ranked

1036  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of donor ferritin testing on blood availability in Canada. <i>Vox Sanguinis</i> , 2022, 117, 17-26.	1.5	6
2	International survey of strategies to mitigate transfusion-transmitted <i>Trypanosoma cruzi</i> in endemic countries, 2016-2018. <i>Vox Sanguinis</i> , 2022, 117, 58-63.	1.5	6
3	HIV residual risk in Canada for apheresis source plasma donation without deferral for men who have sex with men. <i>Vox Sanguinis</i> , 2022, 117, 201-207.	1.5	7
4	Is high hemoglobin a hindrance factor for blood donation? A pilot observational study from the coastal region of India. <i>Transfusion Clinique Et Biologique</i> , 2022, 29, 147-152.	0.4	0
5	HIV incidence and compliance with deferral criteria over three progressively shorter time deferrals for men who have sex with men in Canada. <i>Transfusion</i> , 2022, 62, 125-134.	1.6	14
6	Current challenges of severe acute respiratory syndrome coronavirus 2 seroprevalence studies among blood donors: A scoping review. <i>Vox Sanguinis</i> , 2022, 117, 476-487.	1.5	5
7	An uncertain association between influenza season, recent influenza vaccination campaigns, and unconfirmed repeat reactive syphilis serology assay results in Canadian blood donors. <i>Transfusion</i> , 2022, 62, 510-512.	1.6	0
8	SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. <i>Microbiology Spectrum</i> , 2022, 10, e0226221.	3.0	5
9	Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays. <i>Microbiology Spectrum</i> , 2022, 10, e0256321.	3.0	8
10	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. <i>Microbiology Spectrum</i> , 2022, 10, e0270221.	3.0	3
11	SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e057846.	1.9	14
12	A Prospective Observational Cohort Comparison of SARS-CoV-2 Seroprevalence Between Paramedics and Matched Blood Donors in Canada During the COVID-19 Pandemic. <i>Annals of Emergency Medicine</i> , 2022, 80, 38-45.	0.6	8
13	Canadian blood suppliers: An expanding role in public health surveillance?. <i>Canada Communicable Disease Report</i> , 2022, 48, 124-130.	1.3	6
14	Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era. <i>Microbiology Spectrum</i> , 2022, 10, e0033922.	3.0	9
15	Balancing non-discriminatory donor selection and blood safety in the Netherlands: Evaluation of an individual risk assessment of sexual behavior. <i>Transfusion</i> , 2022, 62, 1241-1250.	1.6	3
16	Assessing unintentional creation of bias against men who have sex with men as a function of exposure to blood donor screening questionnaire: A national randomized controlled trial. <i>Transfusion</i> , 2022, 62, 1399-1407.	1.6	5
17	Whole blood donor return rates after deferral for tattooing or body piercing—Survey across blood donation services: The BEST collaborative study. <i>Vox Sanguinis</i> , 2022, 117, 1085-1089.	1.5	1
18	Behaviour based screening questions and potential donation loss using the for the assessment of individualised risk-screening criteria: A Canadian perspective. <i>Transfusion Medicine</i> , 2022, 32, 422-427.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Staff perspectives on barriers and enablers to implementing alternative source plasma eligibility criteria for gay, bisexual, and other men who have sex with men. <i>Transfusion</i> , 2022, 62, 1571-1582.	1.6	9
20	Research initiatives of blood services worldwide in response to the covid-19 pandemic. <i>Vox Sanguinis</i> , 2021, 116, 296-304.	1.5	22
21	SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. <i>Transfusion</i> , 2021, 61, 862-872.	1.6	48
22	Themed issue " focusing on donor assessment, motivation and vigilance. <i>Vox Sanguinis</i> , 2021, 116, 257-259.	1.5	1
23	Evaluation of a pre-exposure prophylaxis (PrEP)/post-exposure prophylaxis (PEP) deferral policy among blood donors. <i>Transfusion</i> , 2021, 61, 1684-1689.	1.6	10
24	An international comparison of HIV prevalence and incidence in blood donors and general population: a BEST Collaborative study. <i>Vox Sanguinis</i> , 2021, 116, 1084-1093.	1.5	4
25	An international comparison of anti-SARS-CoV-2 assays used for seroprevalence surveys from blood component providers. <i>Vox Sanguinis</i> , 2021, 116, 946-954.	1.5	6
26	Risk of transfusion-transmitted <i>Babesia microti</i> in Canada. <i>Transfusion</i> , 2021, 61, 2958-2968.	1.6	6
27	Early warning and rapid public health response to prevent COVID-19 outbreaks in long-term care facilities (LTCF) by monitoring SARS-CoV-2 RNA in LTCF site-specific sewage samples and assessment of antibodies response in this population: prospective study protocol. <i>BMJ Open</i> , 2021, 11, e052282.	1.9	6
28	<i>Babesia microti</i> in a Canadian blood donor and lookback in a red blood cell recipient. <i>Vox Sanguinis</i> , 2021, , .	1.5	4
29	The estimated risk of SARS-CoV-2 infection via cornea transplant in Canada. <i>Cell and Tissue Banking</i> , 2021, 22, 685-695.	1.1	3
30	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. <i>PLoS ONE</i> , 2021, 16, e0257743.	2.5	13
31	Resistance of SARS-CoV-2 beta and gamma variants to plasma collected from Canadian blood donors during the spring of 2020. <i>Transfusion</i> , 2021, , .	1.6	8
32	HIV residual risk in Canada under a three-month deferral for men who have sex with men. <i>Vox Sanguinis</i> , 2020, 115, 133-139.	1.5	22
33	Evaluating the Clinical Effect of Female Blood Donors of Child-Bearing Age on Maternal and Neonatal Outcomes: A Cohort Study. <i>Transfusion Medicine Reviews</i> , 2020, 34, 117-123.	2.0	5
34	Transfusion-transmitted and community-acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs. <i>American Journal of Transplantation</i> , 2020, 20, 3509-3519.	4.7	3
35	Prevalence of <i>Babesia</i> in Canadian blood donors: June-October 2018. <i>Transfusion</i> , 2019, 59, 3171-3176.	1.6	13
36	Changing the deferral for men who have sex with men " an improved model to estimate HIV residual risk. <i>Vox Sanguinis</i> , 2019, 114, 666-674.	1.5	17

#	ARTICLE	IF	CITATIONS
37	Compliance with time-based deferrals for men who have sex with men. <i>Transfusion</i> , 2019, 59, 916-920.	1.6	27
38	International forum on Occult hepatitis B infection and transfusion safety. <i>Vox Sanguinis</i> , 2019, 114, 397-406.	1.5	23
39	International Forum on Occult hepatitis B infection and transfusion safety. <i>Vox Sanguinis</i> , 2019, 114, e1-e35.	1.5	6
40	Changes in minimum hemoglobin and interdonation interval: impact on donor hemoglobin and donation frequency. <i>Transfusion</i> , 2019, 59, 1734-1741.	1.6	10
41	International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies. <i>Vox Sanguinis</i> , 2019, 114, 17-27.	1.5	15
42	Malaria blood safety policy in five non-endemic countries: a retrospective comparison through the lens of the ABO risk-based decision-making framework. <i>Blood Transfusion</i> , 2019, 17, 94-102.	0.4	12
43	Human T-cell lymphotropic virus: A simulation model to estimate residual risk with universal leucoreduction and testing strategies in Canada. <i>Vox Sanguinis</i> , 2018, 113, 750-759.	1.5	7
44	Moving from a permanent to a 5 year deferral for donors with cured cancer results in a substantial reduction in deferral rates. <i>ISBT Science Series</i> , 2018, 13, 429-431.	1.1	3
45	Two-year follow-up of donors in a large national study of ferritin testing. <i>Transfusion</i> , 2018, 58, 2868-2873.	1.6	11
46	Assignment of cytomegalovirus infection status in infants awaiting solid organ transplant: Viral detection methods as adjuncts to serology. <i>Pediatric Transplantation</i> , 2018, 22, e13229.	1.0	5
47	Residual risk of HIV, HCV and HBV in Canada. <i>Transfusion and Apheresis Science</i> , 2017, 56, 389-391.	1.0	29
48	Impact of informing donors of low ferritin results. <i>Transfusion</i> , 2016, 56, 2193-2198.	1.6	9
49	Donor iron policy: from research to practice. <i>Transfusion</i> , 2016, 56, 1496-1498.	1.6	4
50	Impact of a 5-year deferral from blood donation for men who have sex with men. <i>Transfusion</i> , 2016, 56, 1598-1602.	1.6	21
51	How do I interpret a confidence interval?. <i>Transfusion</i> , 2016, 56, 1680-1683.	1.6	44
52	Seroprevalence of <i>Babesia microti</i> infection in Canadian blood donors. <i>Transfusion</i> , 2016, 56, 237-243.	1.6	27
53	Transfusion-transmitted malaria: is hope around the corner?. <i>Lancet, The</i> , 2016, 387, 1701-1703.	13.7	1
54	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. <i>Lancet Haematology, the</i> , 2016, 3, e246-e254.	4.6	57

#	ARTICLE	IF	CITATIONS
55	The Epidemiology of Imported Malaria and Transfusion Policy in 5 Nonendemic Countries. <i>Transfusion Medicine Reviews</i> , 2015, 29, 162-171.	2.0	53
56	Iron deficiency in Canadian blood donors. <i>Transfusion</i> , 2014, 54, 775-779.	1.6	47
57	Evaluation of selective screening of donors for antibody to <i>Trypanosoma cruzi</i> : seroprevalence of donors who answer "no" to risk questions. <i>Transfusion</i> , 2014, 54, 863-869.	1.6	5
58	Are donors in Canada compliant with deferral for tattoos and piercing?. <i>Blood Transfusion</i> , 2014, 12, 141-2.	0.4	4
59	Impact of changes to policy for Mexican risk travel on Canadian blood donor deferrals. <i>Blood Transfusion</i> , 2013, 11, 580-4.	0.4	6
60	Surveillance of Transfusion-Transmissible Infections. <i>Transfusion Medicine Reviews</i> , 2012, 26, 38-57.	2.0	21
61	Donor understanding and attitudes about current and potential deferral criteria for high-risk sexual behavior. <i>Transfusion</i> , 2011, 51, 1829-1834.	1.6	51
62	Impact of a policy to permit the return of donors repeat reactive to the Abbott PRISM antibody to hepatitis B core antigen assay. <i>Transfusion</i> , 2009, 49, 271-277.	1.6	7
63	Reassessment of deferrals for tattooing and piercing. <i>Transfusion</i> , 2009, 49, 648-654.	1.6	25
64	Assessment of a travel question to identify donors with risk of <i>Trypanosoma cruzi</i> : operational validity and field testing. <i>Transfusion</i> , 2008, 48, 755-761.	1.6	19
65	Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. <i>Transfusion</i> , 2008, 48, 902-909.	1.6	37
66	Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. <i>Transfusion</i> , 2007, 47, 316-325.	1.6	131
67	Hepatitis B virus DNA positive, hepatitis B surface antigen negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. <i>Transfusion</i> , 2007, 47, 1809-1815.	1.6	49
68	The Canadian Blood Donor Health Assessment Questionnaire: Lessons From History, Application of Cognitive Science Principles, and Recommendations for Change. <i>Transfusion Medicine Reviews</i> , 2007, 21, 205-222.	2.0	38
69	Predictive ability of sequential surveys in determining donor loss from increasingly stringent variant Creutzfeldt-Jakob disease deferral policies. <i>Transfusion</i> , 2006, 46, 461-468.	1.6	24
70	Face-to-face interviewing in predonation screening: lack of effect on detected human immunodeficiency virus and hepatitis C virus infections. <i>Transfusion</i> , 2006, 46, 1380-1387.	1.6	18
71	The Canadian donor health assessment questionnaire: can it be improved?. <i>Transfusion</i> , 2006, 46, 2169-2175.	1.6	20
72	Changing donor policy for men who have sex with men: it's all about the data. <i>Annals of Blood</i> , 0, 5, 16-16.	0.4	2

#	ARTICLE	IF	CITATIONS
73	A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021. Microbiology Spectrum, 0, , .	3.0	5